Next Article in Journal / Special Issue
COVID-19 Outbreak Management and Vaccination Strategy in The United States of America
Previous Article in Journal
Sex Differences in Cancer-Specific Survival Are Pronounced during Adolescence and Young Adulthood: A SEER Population-Based Study
Previous Article in Special Issue
Vaccination Is Not Enough: Understanding the Increase in Cases of COVID-19 in Chile despite a High Vaccination Rate
Article

COVID-19 Vaccination Strategy in China: A Case Study

1
Institute of Global Health, University of Geneva, 1211 Geneva, Switzerland
2
Department of Chinese, UFR 2, Université Paul Valéry Montpellier 3, 34199 Montpellier, France
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editors: Michel Kazatchkine and Sana de Courcelles
Received: 19 July 2021 / Revised: 28 August 2021 / Accepted: 30 August 2021 / Published: 3 September 2021
(This article belongs to the Special Issue Vaccination Strategies of COVID-19)
The coronavirus disease 2019 (COVID-19) outbreak in China was first reported to the World Health Organization on 31 December 2019, after the first cases were officially identified around 8 December 2019. However, the case of an infected patient of 55 years old can probably be traced back on 17 November. The spreading has been rapid and heterogeneous. Economic, political and social impacts have not been long overdue. This paper, based on English, French and Chinese research in national and international databases, aims to study the COVID-19 situation in China through the management of the outbreak and the Chinese response to vaccination strategy. The coronavirus disease pandemic is under control in China through non-pharmaceutical interventions, and the mass vaccination program has been launched to further prevent the disease and progressed steadily with 483.34 million doses having been administered across the country by 21 May 2021. China is also acting as an important player in the development and production of SARS-CoV-2 vaccines. View Full-Text
Keywords: COVID-19; SARS-CoV-2; vaccination strategy; China COVID-19; SARS-CoV-2; vaccination strategy; China
Show Figures

Figure 1

MDPI and ACS Style

Mohamadi, M.; Lin, Y.; Vulliet, M.V.S.; Flahault, A.; Rozanova, L.; Fabre, G. COVID-19 Vaccination Strategy in China: A Case Study. Epidemiologia 2021, 2, 402-425. https://0-doi-org.brum.beds.ac.uk/10.3390/epidemiologia2030030

AMA Style

Mohamadi M, Lin Y, Vulliet MVS, Flahault A, Rozanova L, Fabre G. COVID-19 Vaccination Strategy in China: A Case Study. Epidemiologia. 2021; 2(3):402-425. https://0-doi-org.brum.beds.ac.uk/10.3390/epidemiologia2030030

Chicago/Turabian Style

Mohamadi, Marjan, Yuling Lin, Mélissa V.S. Vulliet, Antoine Flahault, Liudmila Rozanova, and Guilhem Fabre. 2021. "COVID-19 Vaccination Strategy in China: A Case Study" Epidemiologia 2, no. 3: 402-425. https://0-doi-org.brum.beds.ac.uk/10.3390/epidemiologia2030030

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop